RVMD

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

Revolution Medicines Announces Major Stock and Notes Offerings to Fuel R&D

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Revolution Medicines aims to raise $750 million through a stock offering and $250 million via convertible senior notes due 2033. Proceeds will primarily support R&amp;D and commercialization activities but may lead to dilution for current shareholders.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Revolution Medicines plans $750 million stock and $250 million notes offerings.</li><li>The offerings will fund R&amp;D and general corporate purposes.</li><li>Investors get conversion options for the notes, set to mature in 2033.</li><li>J.P. Morgan, TD Cowen, and Guggenheim Securities are managing the offerings.</li><li>The stock offering isn&#039;t contingent on the notes offering, and vice versa.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>J.P. Morgan (JPM)</strong>: Acting as lead underwriter for offerings.</li><li><strong>TD Cowen (TD)</strong>: Participating in equity and debt offerings.</li><li><strong>Guggenheim Securities (GUG)</strong>: Providing book-running services for the offerings.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This is a Corporate Developments category news as it relates to financing activities aimed at enhancing operational capacity and funding clinical trials. These actions are critical for future growth prospects in the oncology sector.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Issuing new stock may dilute existing shareholder value.</li><li>Convertible notes could impact future earnings if converted.</li><li>Funding for R&amp;D could accelerate pipeline candidates&#039; development.</li><li>Market conditions could affect the success of the offerings.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Offering includes $750 million of common stock and $250 million of convertible notes.</li><li>Convertible notes mature on May 1, 2033.</li><li>Completion of stock offering is not contingent on the notes offering.</li><li>Underwriters have options to purchase additional common stock and notes.</li><li>Proceeds will fund R&amp;D and operational expenses.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Expect RVMD&#039;s stock to experience volatility and potential dilution post-offering, recommend cautious entry.</p>
  </section>
</section>


<article>
    <h2>Revolution Medicines (RVMD) Announces Major Offerings of Common Stock and Convertible Senior Notes</h2>
    <p>REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a leading player in late-stage clinical oncology, has revealed its plans to initiate public offerings for $750 million of common stock and $250 million of convertible senior notes due 2033. This announcement comes as the company diversifies its financial base to strengthen its capabilities in developing therapies for patients with RAS-addicted cancers, subject to market conditions.</p>

    <section>
        <h3>Details of the Offerings</h3>
        <p>Revolution Medicines will register these separate public offerings under the Securities Act of 1933. Notably, the company may extend a 30-day option for underwriters to purchase an additional $112.5 million of common stock and a further $37.5 million of the notes to cover any over-allotments. Importantly, the successful completion of one offering will not depend on the other, allowing for greater flexibility.</p>
        <p>Leading the offerings, <strong>J.P. Morgan, TD Cowen,</strong> and <strong>Guggenheim Securities</strong> will act as book-running managers.</p>
    </section>

    <section>
        <h3>Convertible Senior Notes Overview</h3>
        <p>The convertible senior notes will be classified as senior, unsecured obligations of Revolution Medicines, accruing interest payable semi-annually and maturing on May 1, 2033, unless otherwise repurchased, redeemed, or converted. Under specified conditions, noteholders may convert their notes into cash, shares of common stock, or a combination of both at Revolution Medicines' discretion.</p>
        <ul>
            <li>The notes are redeemable in part or in full for cash from May 6, 2030, onward.</li>
            <li>Redemption is contingent on the closing price of RVMD’s common stock exceeding 130% of the conversion price for a specified period.</li>
            <li>Noteholders may require the company to repurchase their notes at a set price, under certain circumstances.</li>
        </ul>
    </section>

    <section>
        <h3>Use of Proceeds</h3>
        <p>Proceeds from these offerings will be allocated for general corporate purposes, including substantial investments in research and development, potential commercialization of product candidates, and covering administrative and capital expenses. This financial strategy is critical as Revolution Medicines continues to advance its innovative oncology programs.</p>
    </section>

    <section>
        <h3>SEC Registration and Availability</h3>
        <p>The offerings will proceed under an effective shelf registration statement filed with the Securities and Exchange Commission (SEC). Detailed information, including preliminary prospectus supplements and accompanying documents, can be accessed through the SEC's website at <em>www.sec.gov</em>. For direct inquiries, interested parties may contact J.P. Morgan Securities LLC, TD Securities (USA) LLC, or Guggenheim Securities for copies of the prospectuses.</p>
    </section>

    <section>
        <h3>About Revolution Medicines, Inc.</h3>
        <p>Revolution Medicines is at the forefront of developing targeted therapies for patients with RAS-addicted cancers. Their robust R&D pipeline includes various RAS(ON) inhibitors, such as:</p>
        <ul>
            <li>Daraxonrasib (RMC-6236): a multi-selective RAS(ON) inhibitor.</li>
            <li>Elironrasib (RMC-6291): a G12C-selective RAS(ON) inhibitor.</li>
            <li>Zoldonrasib (RMC-9805): a G12D-selective RAS(ON) inhibitor.</li>
            <li>RMC-5127: a G12V-selective RAS(ON) inhibitor.</li>
        </ul>
        <p>Further development focus includes RAS(ON) mutant-selective inhibitors that could play a transformative role in oncology.</p>
    </section>

    <section>
        <h3>Forward-Looking Statements</h3>
        <p>Forward-looking statements in this announcement include anticipated terms of the offerings and potential use of proceeds. These statements carry inherent uncertainties that could lead actual outcomes to differ materially due to market conditions, volatility in RVMD stock price, and other unforeseen challenges. Revolution Medicines does not commit to updating these statements beyond the announcement date.</p>
    </section>
    
    <footer>
        <p><strong>Media & Investor Contact:</strong> <br>
        <a href="mailto:media@revmed.com">media@revmed.com</a> <br>
        <a href="mailto:investors@revmed.com">investors@revmed.com</a> </p>
    </footer>
</article>

Revolution Medicines aims to raise $750 million through a stock offering and $250 million via convertible senior notes due 2033. Proceeds will primarily support R&D and commercialization activities but may lead to dilution for current shareholders.

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News